NO20034549D0 - Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV - Google Patents
Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IVInfo
- Publication number
- NO20034549D0 NO20034549D0 NO20034549A NO20034549A NO20034549D0 NO 20034549 D0 NO20034549 D0 NO 20034549D0 NO 20034549 A NO20034549 A NO 20034549A NO 20034549 A NO20034549 A NO 20034549A NO 20034549 D0 NO20034549 D0 NO 20034549D0
- Authority
- NO
- Norway
- Prior art keywords
- diabetes
- dipeptidyl peptidase
- inhibitors
- type
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0109146.1A GB0109146D0 (en) | 2001-04-11 | 2001-04-11 | Treatment of type 2 diabetes |
PCT/GB2002/001674 WO2002083109A1 (en) | 2001-04-11 | 2002-04-10 | Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase iv |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20034549L NO20034549L (no) | 2003-10-09 |
NO20034549D0 true NO20034549D0 (no) | 2003-10-09 |
Family
ID=9912727
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20034549A NO20034549D0 (no) | 2001-04-11 | 2003-10-09 | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040209891A1 (ja) |
EP (1) | EP1377278B1 (ja) |
JP (1) | JP2004525179A (ja) |
KR (1) | KR20040025915A (ja) |
CN (1) | CN1248683C (ja) |
AT (1) | ATE344029T1 (ja) |
AU (1) | AU2002244860B2 (ja) |
CA (1) | CA2443229A1 (ja) |
CZ (1) | CZ20032927A3 (ja) |
DE (1) | DE60215787T2 (ja) |
GB (1) | GB0109146D0 (ja) |
HK (1) | HK1059213A1 (ja) |
HU (1) | HUP0303876A3 (ja) |
IL (1) | IL157821A0 (ja) |
MX (1) | MXPA03009224A (ja) |
NO (1) | NO20034549D0 (ja) |
NZ (1) | NZ528172A (ja) |
PL (1) | PL366633A1 (ja) |
RU (1) | RU2328283C2 (ja) |
UA (1) | UA76452C2 (ja) |
WO (1) | WO2002083109A1 (ja) |
ZA (1) | ZA200307156B (ja) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2296979T3 (es) | 2001-06-27 | 2008-05-01 | Smithkline Beecham Corporation | Fluoropirrolidinas como inhibidores de dipeptidil peptidasa. |
GB0125445D0 (en) * | 2001-10-23 | 2001-12-12 | Ferring Bv | Protease Inhibitors |
AU2002952946A0 (en) * | 2002-11-27 | 2002-12-12 | Fujisawa Pharmaceutical Co., Ltd. | Dpp-iv inhibitor |
CN1894234A (zh) | 2003-03-25 | 2007-01-10 | 武田药品工业株式会社 | 二肽基肽酶抑制剂 |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
US7470700B2 (en) | 2003-08-13 | 2008-12-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
JP2007505121A (ja) | 2003-09-08 | 2007-03-08 | 武田薬品工業株式会社 | ジペプチジルぺプチダーゼ阻害剤 |
KR20170104639A (ko) | 2003-11-17 | 2017-09-15 | 노파르티스 아게 | 디펩티딜 펩티다제 ⅳ 억제제의 용도 |
US20070149451A1 (en) * | 2003-11-17 | 2007-06-28 | Holmes David G | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent |
HUE039902T2 (hu) | 2004-01-20 | 2019-02-28 | Novartis Ag | Közvetlenül préselt formula és eljárás |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
BRPI0418639B8 (pt) | 2004-03-15 | 2021-05-25 | Takeda Pharmaceutical | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos |
EP1753730A1 (en) | 2004-06-04 | 2007-02-21 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2006019965A2 (en) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Dipeptidyl peptidase inhibitors |
ATE553077T1 (de) * | 2004-07-23 | 2012-04-15 | Nuada Llc | Peptidaseinhibitoren |
JP2008524331A (ja) | 2004-12-21 | 2008-07-10 | 武田薬品工業株式会社 | ジペプチジルペプチダーゼ阻害剤 |
DOP2006000008A (es) | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
US7553861B2 (en) | 2005-04-22 | 2009-06-30 | Alantos Pharmaceuticals Holding, Inc. | Dipeptidyl peptidase-IV inhibitors |
BRPI0614732A2 (pt) * | 2005-08-11 | 2011-04-12 | Hoffmann La Roche | composição farmacêutica que compreende um inibidor de dpp-iv, uso de um inibidor de dpp-iv e método para o tratamento de enfermidades associadas com nìveis de glicose sanguìnea elevados |
US20070060530A1 (en) | 2005-09-14 | 2007-03-15 | Christopher Ronald J | Administration of dipeptidyl peptidase inhibitors |
CN102675221A (zh) | 2005-09-16 | 2012-09-19 | 武田药品工业株式会社 | 用于制备嘧啶二酮衍生物的方法中的中间体 |
GB0526291D0 (en) | 2005-12-23 | 2006-02-01 | Prosidion Ltd | Therapeutic method |
WO2007112347A1 (en) | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
PE20071221A1 (es) | 2006-04-11 | 2007-12-14 | Arena Pharm Inc | Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
TW200838536A (en) | 2006-11-29 | 2008-10-01 | Takeda Pharmaceutical | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
EP2146210A1 (en) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY |
FR2938999B1 (fr) * | 2008-11-24 | 2011-07-01 | Oreal | Procede de preparation d'un parfum au sein d'un systeme comportant une pluralite de terminaux interactifs de formulation de parfums et un serveur agence pour echanger des donnees avec la pluralite de terminaux |
AR077642A1 (es) | 2009-07-09 | 2011-09-14 | Arena Pharm Inc | Moduladores del metabolismo y el tratamiento de trastornos relacionados con el mismo |
EP2556056A1 (en) | 2010-04-06 | 2013-02-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
WO2012135570A1 (en) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012145361A1 (en) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
US20140038889A1 (en) | 2011-04-22 | 2014-02-06 | Arena Pharmaceuticals, Inc. | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto |
WO2012145604A1 (en) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2012170702A1 (en) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2013055910A1 (en) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulators of the gpr119 receptor and the treatment of disorders related thereto |
WO2014074668A1 (en) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulators of gpr119 and the treatment of disorders related thereto |
GB201415598D0 (en) | 2014-09-03 | 2014-10-15 | Univ Birmingham | Elavated Itercranial Pressure Treatment |
EA201791982A1 (ru) | 2015-03-09 | 2020-02-17 | Интекрин Терапьютикс, Инк. | Способы лечения неалкогольной жировой болезни печени и/или липодистрофии |
WO2018162722A1 (en) | 2017-03-09 | 2018-09-13 | Deutsches Institut Für Ernährungsforschung Potsdam-Rehbrücke | Dpp-4 inhibitors for use in treating bone fractures |
MX2019011867A (es) | 2017-04-03 | 2020-01-09 | Coherus Biosciences Inc | Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva. |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL111785A0 (en) * | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
DE19616486C5 (de) * | 1996-04-25 | 2016-06-30 | Royalty Pharma Collection Trust | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
DE19823831A1 (de) * | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
US7396809B1 (en) * | 1999-02-10 | 2008-07-08 | Curis, Inc. | Methods and reagents for treating glucose metabolic disorders |
GB9906714D0 (en) * | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
US6110949A (en) * | 1999-06-24 | 2000-08-29 | Novartis Ag | N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
US6107317A (en) * | 1999-06-24 | 2000-08-22 | Novartis Ag | N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
EP1228061A4 (en) * | 1999-11-12 | 2004-12-15 | Guilford Pharm Inc | DIPEPTIDYL PEPTIDASE IV INHIBITORS, METHOD FOR THE PRODUCTION AND USE THEREOF |
GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
PT1283735E (pt) * | 2000-03-31 | 2009-03-19 | Prosidion Ltd | Processo para melhoramento da sinalização de ilhéus na diabetes mellitus e para a sua prevenção |
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
GB0014969D0 (en) * | 2000-06-19 | 2000-08-09 | Smithkline Beecham Plc | Novel method of treatment |
-
2001
- 2001-04-11 GB GBGB0109146.1A patent/GB0109146D0/en not_active Ceased
-
2002
- 2002-04-10 JP JP2002580913A patent/JP2004525179A/ja not_active Withdrawn
- 2002-04-10 DE DE60215787T patent/DE60215787T2/de not_active Expired - Fee Related
- 2002-04-10 CN CNB028080955A patent/CN1248683C/zh not_active Expired - Fee Related
- 2002-04-10 PL PL02366633A patent/PL366633A1/xx unknown
- 2002-04-10 CZ CZ20032927A patent/CZ20032927A3/cs unknown
- 2002-04-10 EP EP02713070A patent/EP1377278B1/en not_active Expired - Lifetime
- 2002-04-10 HU HU0303876A patent/HUP0303876A3/hu unknown
- 2002-04-10 MX MXPA03009224A patent/MXPA03009224A/es active IP Right Grant
- 2002-04-10 CA CA002443229A patent/CA2443229A1/en not_active Abandoned
- 2002-04-10 NZ NZ528172A patent/NZ528172A/en unknown
- 2002-04-10 RU RU2003132687/14A patent/RU2328283C2/ru not_active IP Right Cessation
- 2002-04-10 WO PCT/GB2002/001674 patent/WO2002083109A1/en active IP Right Grant
- 2002-04-10 AU AU2002244860A patent/AU2002244860B2/en not_active Ceased
- 2002-04-10 KR KR10-2003-7013350A patent/KR20040025915A/ko not_active Application Discontinuation
- 2002-04-10 IL IL15782102A patent/IL157821A0/xx unknown
- 2002-04-10 US US10/474,676 patent/US20040209891A1/en not_active Abandoned
- 2002-04-10 AT AT02713070T patent/ATE344029T1/de not_active IP Right Cessation
- 2002-10-04 UA UA2003109184A patent/UA76452C2/uk unknown
-
2003
- 2003-09-12 ZA ZA200307156A patent/ZA200307156B/en unknown
- 2003-10-09 NO NO20034549A patent/NO20034549D0/no not_active Application Discontinuation
-
2004
- 2004-03-11 HK HK04101781A patent/HK1059213A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO20034549L (no) | 2003-10-09 |
PL366633A1 (en) | 2005-02-07 |
HK1059213A1 (en) | 2004-06-25 |
WO2002083109A1 (en) | 2002-10-24 |
GB0109146D0 (en) | 2001-05-30 |
HUP0303876A2 (hu) | 2004-03-01 |
HUP0303876A3 (en) | 2005-06-28 |
ZA200307156B (en) | 2004-06-04 |
IL157821A0 (en) | 2004-03-28 |
ATE344029T1 (de) | 2006-11-15 |
CN1248683C (zh) | 2006-04-05 |
RU2003132687A (ru) | 2005-04-10 |
NZ528172A (en) | 2004-09-24 |
US20040209891A1 (en) | 2004-10-21 |
DE60215787T2 (de) | 2007-08-30 |
CZ20032927A3 (cs) | 2004-06-16 |
UA76452C2 (en) | 2006-08-15 |
JP2004525179A (ja) | 2004-08-19 |
EP1377278A1 (en) | 2004-01-07 |
CN1501796A (zh) | 2004-06-02 |
KR20040025915A (ko) | 2004-03-26 |
CA2443229A1 (en) | 2002-10-24 |
DE60215787D1 (de) | 2006-12-14 |
RU2328283C2 (ru) | 2008-07-10 |
AU2002244860B2 (en) | 2006-11-16 |
MXPA03009224A (es) | 2004-01-29 |
EP1377278B1 (en) | 2006-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20034549D0 (no) | Behandling av type 2 diabetes med inhibitorer av dipeptidyl peptidase IV | |
MY151032A (en) | Treatment of tnf? related disorders | |
NO20050807L (no) | Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser | |
TW200510349A (en) | Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor | |
DK1373215T3 (da) | Gelanamycinderivater egnet til behandling af cancer | |
NO20055894L (no) | Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer | |
NO20045056L (no) | Fremgangsmater for behandling av hepatitt | |
CY1111999T1 (el) | Λακτοφερρινη στην αγωγη κακοηθων νεοπλασματων και αλλων υπερπλαστικων νοσων | |
NO20060328L (no) | Kombinasjon av mGluR2-antagonist og ACHE-inhibitor for behandiing av akutt og/eller kronisk neurologiske forstyrrelser | |
SE0301886D0 (sv) | New use V | |
WO2004010937A3 (en) | Method of treating cancer | |
ATE402176T1 (de) | Pyrrolidin- und azetidinverbindungen alsccr5- antagonisten | |
RS52825B (en) | PROCEDURES FOR THE TREATMENT OF DISORDERS OR DISEASES RELATED TO HYPERLIPIDEMIA AND HYPERHOLESTEROLEMIA WITH MINIMIZATION OF ADVERSE EFFECTS | |
NO20045370L (no) | Anvendelse av docetaxel/doxorubicin/cyklofosfamid i adjuvansterapi av bryst og ovariekreft | |
WO2004110392A3 (en) | Compositions and methods for treating coronavirus infection and sars | |
WO2005081972A3 (en) | Maleiimide anti-tumor phosphatase inhibitors | |
TW200503666A (en) | Treatment of type 1 diabetes with pde5 inhibitors | |
SE0301883D0 (sv) | New use II | |
RS50681B (sr) | Kombinacija taksana i ciklin-zavisne kinaze | |
ATE302008T1 (de) | Behandlung von entzündlichen erkrankungen | |
NO20042056L (no) | Farmasoytisk sammensetning for anvendelse ved behandling av malignanser som innbefatter en kombinasjon av et bisfosfonat, en COX-2 inhibitor og et taksol | |
SE0301885D0 (sv) | New use IV | |
FR2839450B1 (fr) | Preparation medicamenteuse notamment pour le traitement des hernies discales | |
NO20051936L (no) | Anvendelse av 4-pyridylmetyl-ftalazinderivater for fremstilling av et medikament for behandling av myelodysplastiske syndromer. | |
ATE392213T1 (de) | Verwendung von gamma-gt inhibitoren zur behandlung von chronischen degenerativerkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |